Blastomycosis

Blastomycosis Market Outlook

The global Blastomycosis market is projected to reach a significant size of approximately USD 1.1 billion by 2035, with a compound annual growth rate (CAGR) of around 7.2% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of blastomycosis infections, particularly in endemic regions, expanding awareness of fungal infections, and advancements in diagnostic techniques. The rising demand for effective antifungal therapies and the growing healthcare expenditure globally are further propelling the market. Additionally, ongoing research and development of new medications and treatment protocols are likely to enhance the growth trajectory of this market.

Growth Factor of the Market

One of the primary growth factors driving the Blastomycosis market is the rising incidence of blastomycosis infections, which are often misdiagnosed due to their nonspecific symptoms. Improved diagnostic capabilities, including the use of molecular techniques and serological tests, are aiding in the early detection of the disease, which, in turn, is increasing the demand for antifungal treatments. Furthermore, as healthcare systems in various regions strengthen, access to treatment options for fungal infections is improving, thereby contributing to market growth. The rise in immunocompromised populations, including patients undergoing chemotherapy, those with HIV/AIDS, and organ transplant recipients, is also heightening the susceptibility to blastomycosis, leading to increased treatment demand. Lastly, the development of more effective antifungal medications and treatment regimens is expected to further stimulate market expansion.

Key Highlights of the Market

• The market is anticipated to grow at a CAGR of 7.2% from 2025 to 2035.
• The rise in diagnostic techniques is facilitating the early detection of blastomycosis.
• North America is projected to hold a significant share of the market, driven by higher prevalence rates.
• Advancements in antifungal medications are enhancing treatment options for patients.
• Increasing public health awareness regarding fungal infections is expected to boost market growth.

By Product Type

Antifungal Medications :

Antifungal medications represent the largest segment in the Blastomycosis market, as they are essential for the effective treatment of this fungal infection. Common antifungal agents such as Amphotericin B and Itraconazole are routinely prescribed to manage severe cases of blastomycosis. These medications can be administered intravenously or orally, depending on the severity of the infection. The growing prevalence of blastomycosis, particularly in North America, has led to increased demand for effective antifungal therapies. Additionally, ongoing research aimed at developing novel antifungal agents is likely to enhance the efficacy and safety profiles of treatments, further bolstering this segment's growth.

Antibiotics :

Though antibiotics are primarily used to treat bacterial infections, they still play a role in the management of blastomycosis complications that may arise from co-infections. The awareness of the potential for concurrent infections in patients with blastomycosis has led healthcare providers to consider antibiotic prophylaxis or treatment in conjunction with antifungal therapy. This segment is expected to experience steady growth as more clinicians recognize the importance of addressing secondary infections in managing blastomycosis effectively. The development of broad-spectrum antibiotics that can be used in conjunction with antifungals will further enhance this segment's relevance in patient care.

Antipyretics :

Antipyretics are used to manage fever associated with blastomycosis and are thus an important supportive treatment. Patients suffering from blastomycosis may experience high fever as their body responds to the infection. Antipyretics such as acetaminophen and ibuprofen can provide symptomatic relief and improve patient comfort. The growth of this segment is anticipated to remain modest, as antipyretics do not directly treat the underlying infection; however, their use remains critical in the holistic management of patients with blastomycosis. As awareness of the disease increases, the need for adjunctive therapies such as antipyretics is also likely to rise.

Analgesics :

Analgesics are employed to relieve pain that may occur in patients with severe blastomycosis, particularly those with pulmonary manifestations. The pain varies in intensity and can significantly affect the quality of life. Opioids and non-opioid analgesics may be prescribed to manage pain effectively. The growth of this segment is closely linked to the overall management of patient symptoms, underscoring the need for comprehensive treatment strategies. With the rising incidence of chronic pain conditions associated with severe fungal infections, the analgesics segment is poised for expansion as healthcare providers prioritize pain management in their treatment protocols.

Others :

This category includes various supportive medications and therapies that assist in managing the overall health of patients suffering from blastomycosis. This could encompass corticosteroids to reduce inflammation, and other adjunctive therapies that enhance treatment outcomes. Although this segment may not hold a substantial market share compared to antifungal medications, it is gaining recognition for its role in comprehensive patient care. As research continues to explore the interplay of various treatment modalities in managing blastomycosis, the 'Others' segment may evolve with more specialized treatments emerging.

By Application

Hospitals :

Hospitals are a major application segment for the Blastomycosis market, as these facilities offer comprehensive care for severe infections. Inpatient management allows for close monitoring of patients, especially those with complicated or disseminated cases of blastomycosis. The utilization of advanced medical technology and expert personnel in hospitals enhances the ability to diagnose and treat the disease effectively. The growing burden of fungal infections in hospital settings is prompting healthcare systems to enhance their infection control protocols and treatment regimens, which is favorable for the market. Moreover, hospitals are increasingly collaborating with research institutions to develop novel therapies, which is expected to drive further growth.

Clinics :

Clinics play an essential role in the early diagnosis and management of blastomycosis, particularly for less severe cases that do not require hospitalization. Outpatient clinics provide accessible care for patients who may exhibit mild symptoms or who need follow-up treatment after an initial hospital stay. The rising number of clinics offering specialized services in infectious diseases is contributing to the growth of this segment. Additionally, increased public awareness of blastomycosis is leading more patients to seek care at clinics, further expanding the market. Clinics are also integrating advanced diagnostic tools, thereby improving the overall accuracy of diagnosis and treatment efficacy.

Ambulatory Surgical Centers :

Ambulatory Surgical Centers (ASCs) have emerged as a significant application segment for the Blastomycosis market, particularly for cases requiring minor surgical interventions. These centers provide a cost-effective alternative for patients who need procedures such as drainage of abscesses or other surgical treatments associated with severe blastomycosis cases. The convenience and efficiency of ASCs attract patients who prefer outpatient services. With the increase in the number of surgical procedures being performed in ASCs, the demand for related medications and therapies is also expected to grow. Furthermore, the emphasis on minimally invasive techniques aligns with the market's trend toward more patient-centric care.

Others :

The 'Others' category encompasses various applications related to healthcare settings where blastomycosis treatment may occur. This could include home healthcare services, telemedicine platforms, and rehabilitation centers that provide support for patients recovering from severe infections. As healthcare continues to evolve, the significance of these alternative care settings in managing blastomycosis is increasing. The integration of digital health solutions is expected to facilitate better monitoring and follow-up care for patients, thereby enhancing outcomes. Continued advancements in healthcare delivery models will broaden the application scope for blastomycosis treatment, contributing to overall market growth.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies are a vital distribution channel for the Blastomycosis market, as they provide immediate access to antifungal medications and supportive therapies required for treating infected patients. These pharmacies play a crucial role in ensuring that medications are readily available for intravenous and oral administration within the hospital setting. The comprehensive care model of hospitals enables pharmacists to work closely with healthcare teams, optimizing medication management and ensuring appropriate therapeutic regimens. As hospitals increasingly focus on improving patient outcomes through personalized medicine, the importance of hospital pharmacies in the Blastomycosis market will continue to grow.

Retail Pharmacies :

Retail pharmacies serve as an important distribution channel for outpatient treatment of blastomycosis, especially for patients who are stable and require ongoing management. These pharmacies provide easy access to medications, including antifungal agents, analgesics, and antipyretics, in community settings. The rising prevalence of blastomycosis is prompting retail pharmacies to increase their inventory of antifungal medications and enhance their patient counseling services. Additionally, retail pharmacies are implementing strategies to raise awareness about fungal infections, further solidifying their position in the market. The convenience of obtaining medications from local pharmacies is expected to drive growth in this segment.

Online Pharmacies :

Online pharmacies have gained traction as a distribution channel for the Blastomycosis market, particularly with the increasing trend of e-commerce in healthcare. Patients can order antifungal medications and related therapies from the comfort of their homes, which is particularly appealing in the context of convenience and accessibility. The growth of telehealth services and the rising acceptance of online health services are contributing to the expansion of this channel. Furthermore, online pharmacies often provide competitive pricing and home delivery options, making it easier for patients to access necessary medications. As consumer trust in online healthcare platforms grows, the online pharmacy segment is likely to see significant growth.

Others :

The 'Others' category in distribution channels includes specialized distribution networks, wholesalers, and institutional pharmacies that supply medications to clinics, ASCs, and other healthcare settings. These alternative distribution channels play an important role in ensuring that healthcare providers have timely access to necessary medications for treating blastomycosis. As healthcare providers increasingly rely on a variety of distribution networks, the demand for diverse supply chain solutions is expected to rise. The integration of technology in inventory management and medication distribution will further enhance the efficiency of this segment, contributing to the overall growth of the Blastomycosis market.

By Ingredient Type

Amphotericin B :

Amphotericin B is one of the most widely used antifungal agents for treating severe cases of blastomycosis, especially in immunocompromised patients. It is known for its broad-spectrum effectiveness against various fungal pathogens, making it a cornerstone of treatment protocols. Amphotericin B is typically administered intravenously, and its efficacy in managing serious infections significantly contributes to its demand. While the drug can have potential side effects, advances in formulation and administration techniques are helping to mitigate these concerns. As the prevalence of blastomycosis continues to rise, the demand for Amphotericin B is expected to remain robust within the market.

Itraconazole :

Itraconazole is another critical antifungal agent commonly prescribed for the treatment of blastomycosis, especially in less severe cases or as a follow-up treatment after initial therapy with Amphotericin B. This oral medication is favored for its ease of administration and favorable safety profile compared to other antifungals. The growing recognition of blastomycosis in endemic regions is leading to an increase in the use of Itraconazole as a first-line treatment. Furthermore, the development of generic formulations has made Itraconazole more accessible to patients, thereby enhancing its position in the market.

Fluconazole :

Fluconazole, while not the first choice for treating blastomycosis, is utilized in certain cases, particularly for patients who may be resistant to other antifungal medications. Its oral administration and broader availability make it a valuable option in outpatient settings. The use of Fluconazole may also be considered for prophylactic treatment in high-risk populations, further expanding its application within the market. As healthcare providers continue to explore various treatment options for fungal infections, Fluconazole's role in the management of blastomycosis may grow, albeit at a slower rate compared to more traditional antifungal agents.

Voriconazole :

Voriconazole is an antifungal medication that has been gaining traction in the treatment of various fungal infections, including blastomycosis. Although primarily used for other indications, the drug's broad-spectrum activity makes it a viable option for patients whose infections do not respond to standard therapies. The increasing emphasis on tailored treatment regimens in infectious disease management is likely to boost the demand for Voriconazole as an alternative treatment option. Additionally, ongoing research into its efficacy against specific fungal pathogens will help further define its role in the Blastomycosis market.

Others :

The 'Others' category for ingredient types includes a range of antifungal agents and adjunctive therapies that may complement primary treatments for blastomycosis. This segment may encompass various novel antifungal compounds currently under investigation or medications repurposed for fungal infections. As the understanding of fungal pathogens improves, the potential for new treatment options will increase, fostering innovation in this area. The emphasis on personalized medicine and targeted therapies may spur the development of additional antifungal agents that can be categorized under 'Others.'

By Region

The regional analysis of the Blastomycosis market indicates that North America is poised to hold the largest market share, primarily due to the higher prevalence of the disease in this region. The CDC estimates that approximately 1,000 cases of blastomycosis are reported annually in the U.S., predominantly in states like Wisconsin and Minnesota. This high incidence necessitates robust treatment options and healthcare readiness, contributing to the significant market size in North America. The CAGR for this region is projected to be around 8.0%, driven by ongoing research initiatives and increased public health awareness regarding fungal infections.

Europe follows as the second-largest market, with a growing awareness of blastomycosis and an increase in healthcare expenditure across major economies. The region is also witnessing improvements in diagnostic capabilities, leading to enhanced detection rates. The European market is expected to grow steadily at a CAGR of approximately 6.5% during the forecast period. The Asia Pacific region is anticipated to exhibit the fastest growth rate, fueled by an increasing population, rising healthcare access, and growing awareness of fungal infections. As more countries in this region develop their healthcare infrastructure, the Blastomycosis market is expected to expand significantly. Other regions, such as Latin America and the Middle East & Africa, also show potential for growth, but they currently lag behind in terms of disease prevalence and treatment access.

Opportunities

The Blastomycosis market presents several opportunities for stakeholders to explore, particularly in the area of research and development. With ongoing advancements in biotechnology and pharmaceutical sciences, there is potential for the development of novel antifungal agents that can specifically target blastomycosis pathogens with greater efficacy and fewer side effects. Companies investing in innovative drug development are likely to gain a competitive advantage, as healthcare providers and patients increasingly seek effective and safe treatment options. Furthermore, collaborations between research institutions and pharmaceutical companies can accelerate the pace of discovery and help bring new therapies to market more quickly. Additionally, as awareness of blastomycosis grows, particularly in endemic areas, there will be an increasing demand for education and training programs for healthcare professionals on the latest treatment protocols and diagnostic techniques, presenting further opportunities for market players.

Another key opportunity lies in the expansion of telemedicine and digital health platforms. As healthcare continues to evolve, the adoption of telehealth services is enabling patients to access medical consultations and treatment recommendations without needing to visit healthcare facilities physically. This shift can improve patient engagement, especially in rural or underserved areas where access to specialized fungal infection treatment may be limited. By leveraging telemedicine, healthcare providers can enhance patient monitoring and follow-up care for those undergoing treatment for blastomycosis. As the market landscape evolves, organizations that adapt to these changes and harness technology to improve patient outcomes will likely succeed in capturing a larger share of the market.

Threats

One of the major threats facing the Blastomycosis market is the potential for drug resistance among fungal pathogens. As antifungal medications are used more frequently, the likelihood of developing resistant strains increases, posing significant challenges for treatment efficacy. The emergence of resistant strains could lead to treatment failures and increased mortality rates, raising concerns among healthcare providers. Continuous monitoring and surveillance of fungal pathogens are essential to mitigate this threat. Furthermore, the development of new antifungal agents can be a lengthy and costly process, which may hinder timely market responses to emerging resistance. Companies must remain vigilant and responsive to these threats to ensure that they can provide effective treatment options for patients.

Another threat to the market is the potential for economic constraints and budget cuts within healthcare systems, particularly in regions where resources are already limited. Budgetary constraints may lead to reduced funding for research initiatives and public health programs aimed at combating fungal infections, including blastomycosis. This can stifle innovation and hinder the development of new treatments, ultimately limiting patient access to effective therapies. Additionally, the increasing prevalence of other infectious diseases may divert attention and resources away from fungal infections, further exacerbating the challenges faced by the Blastomycosis market. Stakeholders must advocate for sustainable funding and prioritize the importance of addressing fungal infections within the broader context of public health.

Competitor Outlook

• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Fujifilm Diosynth Biotechnologies
• Mylan N.V.
• Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• Amgen Inc.
• Seagen Inc.

The competitive landscape of the Blastomycosis market is characterized by a mix of pharmaceutical companies and biotechnology firms that are actively involved in the development and distribution of antifungal medications. The key players focus on advancing their product portfolios through research and development, strategic partnerships, and collaborations with healthcare institutions. As the market grows, companies are increasingly investing in innovative therapies that target fungal pathogens and improve patient outcomes. The competitive dynamics are expected to shift as new entrants bring novel treatment options to market, intensifying competition among established firms.

Gilead Sciences, Inc. is a prominent player in the antifungal space, known for its development of innovative therapies. The company has invested significantly in research to enhance its antifungal portfolio, ensuring it remains at the forefront of treatment options for blastomycosis. Astellas Pharma Inc. is another key competitor that focuses on developing antifungal medications, emphasizing the importance of patient safety and effective treatment. Their commitment to research and innovation positions them as a leader in addressing fungal infections. Pfizer Inc. has a long-standing history in the pharmaceutical industry and offers a range of antifungal agents. The company's extensive distribution network ensures that its products reach healthcare providers and patients effectively.

Merck & Co., Inc. has also made significant contributions to the antifungal market, with a focus on developing treatments that address unmet medical needs. The company's ongoing research initiatives and commitment to improving patient access to quality medications reinforce its competitive position. Novartis AG is known for its comprehensive approach to healthcare, including antifungal treatments. Their strategic investments in R&D and collaborations with academic institutions are expected to yield new therapies for blastomycosis. The strength of these companies lies not only in their product offerings but also in their ability to navigate regulatory challenges and adapt to changing market dynamics, positioning them well for future growth.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Seagen Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Astellas Pharma Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hoffmann-La Roche Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Fujifilm Diosynth Biotechnologies
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Blastomycosis Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Ambulatory Surgical Centers
    • 6.1.4 Others
  • 6.2 Blastomycosis Market, By Product Type
    • 6.2.1 Antifungal Medications
    • 6.2.2 Antibiotics
    • 6.2.3 Antipyretics
    • 6.2.4 Analgesics
    • 6.2.5 Others
  • 6.3 Blastomycosis Market, By Ingredient Type
    • 6.3.1 Amphotericin B
    • 6.3.2 Itraconazole
    • 6.3.3 Fluconazole
    • 6.3.4 Voriconazole
    • 6.3.5 Others
  • 6.4 Blastomycosis Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Blastomycosis Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Blastomycosis market is categorized based on

By Product Type

• Antifungal Medications
• Antibiotics
• Antipyretics
• Analgesics
• Others

By Application

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Amphotericin B
• Itraconazole
• Fluconazole
• Voriconazole
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Fujifilm Diosynth Biotechnologies
• Mylan N.V.
• Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• Amgen Inc.
• Seagen Inc.